Filing Flows › Health Care › Personalis (PSNL)
Personalis (PSNL) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Personalis (PSNL) Q3 2026 earnings results →
Q3 2026 Revenue up 77% year over year to $25.6M · 132¢ of every $1 of revenue lost · operating margin -138.8%
Personalis made $25.6M in Q3 2026 (+77% Y/Y). Operating margin -138.8%, net loss $33.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $25.6M in Q3 2026, up 77% year over year and up 14% from the previous quarter.
Operating costs exceeded revenue by $35.5M, an operating margin of -138.8%. Total costs grew 62% against revenue growth of 77%. The fastest-growing cost line was SG&A (+100%). The quarter ended with a net loss of $33.8M, wider than the previous quarter's $31.7M loss.
Operating cash flow was −$27.1M. Non-cash charges added back $2.5M of depreciation and amortization and $3.9M of share-based compensation. Capital expenditures of $3.1M exceeded it, leaving free cash flow of −$30.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $25.6M | +77% | -138.8% | −$33.8M | −$27.1M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $22.4M | +30% | -150.2% | −$31.7M | −$25.8M |
| Q1 2026 | 10-Q | May 7, 2026 | $15.5M | -25% | -207.9% | −$30.0M | −$22.5M |
| Q4 2025 | 10-K | Feb 26, 2026 | $17.3M | +3% | -145.7% | −$23.8M | −$22.2M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $14.5M | -44% | -160.7% | −$21.7M | −$21.8M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $17.2M | -24% | -126.7% | −$20.1M | −$12.9M |
| Q1 2025 | 10-Q | May 6, 2025 | $20.6M | +6% | -85.9% | −$15.8M | −$18.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
About Personalis
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X ( Twitter ).
In its own words, from its 8-K, filed Aug 4, 2026.
Personalis against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +77% against the peers' median +25%. Operating margin: -138.8% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PSNL Personalis | Q3 2026 | $25.6M | +77% | -138.8% |
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
Source: Personalis 10-Q on SEC EDGAR · CIK 1527753 · Services-Medical Laboratories
Guidance and outlook
13F: who owns PSNL and who is buying
More on PSNL
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results